

Elizabeth I Buchbinder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6214153/publications.pdf>

Version: 2024-02-01

42
papers

5,994
citations

279798

23
h-index

276875

41
g-index

45
all docs

45
docs citations

45
times ranked

11531
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
2	Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with Cancer. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e357-e363.	1.2	9
3	Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. <i>Science Advances</i> , 2022, 8, eabl6339.	10.3	6
4	Immune Checkpoint Therapies for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 99-109.	2.2	4
5	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2209-2221.	4.2	32
6	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , 2021, 27, 515-525.	30.7	248
7	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021, 10, 2627-2635.	2.8	5
8	Long-term Overall Survival and Predictors in Anti-PD-1-naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021, 44, 307-318.	2.4	4
9	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. <i>Haematologica</i> , 2021, 106, 651-654.	3.5	4
10	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
11	Cancer Therapy Targeting CD47/SIRPα. <i>Cancers</i> , 2021, 13, 6229.	3.7	20
12	Prognostic Gene Expression Profiling in Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 1004.	4.1	59
13	Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis. <i>Scientific Reports</i> , 2020, 10, 17536.	3.3	2
14	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). <i>Melanoma Management</i> , 2020, 7, MMT41.	0.5	3
15	Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1296-1311.	9.4	49
16	Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. <i>JCO Oncology Practice</i> , 2020, 16, e933-e942.	2.9	33
17	Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. <i>World Neurosurgery</i> , 2020, 139, 226-231.	1.3	5
18	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. <i>Cancer</i> , 2020, 126, 3758-3767.	4.1	37

#	ARTICLE	IF	CITATIONS
19	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	30.7	133
20	Immunotherapy Toxicity. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 275-290.	2.2	23
21	Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. , 2019, 7, 89.		108
22	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
23	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	9.4	283
24	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	28.9	892
25	Clinical Features of Acquired Resistance to Anti-“PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362.	3.4	40
26	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. <i>Clinical Cancer Research</i> , 2017, 23, 4671-4679.	7.0	110
27	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	3.4	114
28	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221.	27.8	2,112
29	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.6	51
30	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. <i>Journal of Neuro-Oncology</i> , 2016, 129, 389-393.	2.9	7
31	Biomarkers in Melanoma: Lessons from Translational Medicine. <i>Trends in Cancer</i> , 2016, 2, 305-312.	7.4	11
32	Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 57-63.	1.3	29
33	A phase I trial of panobinostat (<sc>LBH</sc>589) in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 3041-3050.	2.8	51
34	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	10.7	293
35	Immune-checkpoint blockade “ durable cancer control. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 77-78.	27.6	71
36	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234.	7.1	534

#	ARTICLE	IF	CITATIONS
37	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. <i>Cancer</i> , 2015, 121, 4007-4015.	4.1	56
38	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. <i>Frontiers in Oncology</i> , 2015, 5, 202.	2.8	201
39	Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 755-763.	2.5	28
40	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2015, 125, 3377-3383.	8.2	146
41	Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3210-3218.	4.1	21
42	Interferon, Interleukin-2, and Other Cytokines. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 571-583.	2.2	18